Alnylam Pharmaceuticals Stock Forecast, Price & News

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

Is Alnylam Pharmaceuticals a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alnylam Pharmaceuticals stock.
View analyst ratings for Alnylam Pharmaceuticals or view top-rated stocks.

How has Alnylam Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY stock has increased by 79.5% and is now trading at $182.85.
View which stocks have been most impacted by COVID-19.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Alnylam Pharmaceuticals.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing the Zacks' consensus estimate of ($1.51) by $0.21. The biopharmaceutical company had revenue of $187.63 million for the quarter, compared to analysts' expectations of $218.69 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 94.37% and a negative net margin of 111.82%. The company's revenue for the quarter was up 49.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.18) EPS.
View Alnylam Pharmaceuticals' earnings history.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $790 million-$865 million, compared to the consensus revenue estimate of $853.11 million.

What price target have analysts set for ALNY?

16 Wall Street analysts have issued 1 year price objectives for Alnylam Pharmaceuticals' stock. Their forecasts range from $47.00 to $275.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $198.13 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price.
View analysts' price targets for Alnylam Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:

• John M. Maraganore, Chief Executive Officer & Director (LinkedIn Profile)
• Yvonne L. Greenstreet, President & Chief Operating Officer (LinkedIn Profile)
• Jeffrey V. Poulton, Executive VP, Chief Financial & Accounting Officer
• Akshay K. Vaishnaw, President-Research & Development (LinkedIn Profile)
• Pushkal Garg, Chief Medical Officer

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Alnylam Pharmaceuticals' key competitors?

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of ALNY's competitors.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (8.76%), BlackRock Inc. (7.46%), Wellington Management Group LLP (6.16%), Morgan Stanley (1.57%), The Manufacturers Life Insurance Company (1.45%) and Geode Capital Management LLC (1.22%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals.

Which institutional investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Maverick Capital Ltd., Caption Management LLC, Bellevue Group AG, Farallon Capital Management LLC, Rockefeller Capital Management L.P., International Biotechnology Trust PLC, and Bridger Management LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Jeffrey W Dunn, John Maraganore, Laurie Keating, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, BlackRock Inc., Polar Capital Holdings Plc, Baillie Gifford & Co., Franklin Resources Inc., Natixis, Jane Street Group LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Alnylam Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $182.85.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals has a market capitalization of $21.87 billion and generates $492.85 million in revenue each year. The biopharmaceutical company earns $-858.28 million in net income (profit) each year or ($7.13) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals employs 1,453 workers across the globe.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Where are Alnylam Pharmaceuticals' headquarters?

Alnylam Pharmaceuticals is headquartered at 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at [email protected], or via fax at 617-551-8101.